Detecting familial hypercholesterolemia: An observational study leveraging mandatory universal pediatric total cholesterol screening in Slovakia
- PMID: 38955586
- DOI: 10.1016/j.jacl.2024.03.009
Detecting familial hypercholesterolemia: An observational study leveraging mandatory universal pediatric total cholesterol screening in Slovakia
Abstract
Background: In Slovakia, a mandatory national universal pediatric total cholesterol (TC) screening program is in place to identify cases of familial hypercholesterolemia (FH). However, the program's effectiveness has not been systematically assessed.
Objective: This study aimed to estimate the prevalence of FH among parents of children that had elevated TC levels identified during screening.
Methods: This prospective, non-interventional, observational study enrolled parents of 11-year-old children who underwent TC screening in 23 selected pediatric outpatient clinics between 2017 and 2018. FH was diagnosed using the Dutch Lipid Clinic Network (DLCN) criteria and targeted next-generation sequencing. The primary objective was to estimate the proportion of children with a TC level of >188 mg/dL (>4.85 mmol/L) who had a parent with a confirmed diagnosis of FH.
Results: A total of 112 parents of 56 children with an elevated TC level were enrolled. Five children (8.9%) had a parent in whom FH was genetically confirmed. Without genetic analysis, all five parents would only be diagnosed with "possible FH" by DLCN criteria. Of parents, 83.9% (n = 94/112) had an low-density lipoprotein cholesterol (LDL-C) level of >116 mg/dL (>3 mmol/L), but only 5.3% (n = 5/94) received lipid-lowering therapy. Among the five parents with genetically confirmed FH, all had an LDL-C level >116 mg/dL (>3 mmol/L), with a mean (±SD) of 191 (±24) mg/dL (4.94 [±0.61] mmol/L). Only two of these parents received lipid-lowering therapy.
Conclusions: The present study demonstrates the significance of mandatory universal pediatric TC screening in identifying families with FH and other at-risk families in need of lipid-lowering therapy.
Keywords: Cholesterol; Familial hypercholesterolemia; Family screening; Registry; Slovakia.
Copyright © 2024. Published by Elsevier Inc.
Conflict of interest statement
Declaration of Competing Interest K. R. received lecture fees from Amgen, Novartis, Sanofi, Novo Nordisk, Mylan, and Boehringer Ingelheim. T. F. was supported by the National Institute for Research of Metabolic and Cardiovascular Diseases (Program EXCELES, ID Project No. LX22NPO5104), funded by the European Union – Next Generation EU. T. F. also received honoraria from Novartis in the last three years outside the submitted work. B. V. received honoraria from Amgen, Novartis, Sanofi, Novo Nordisk, Viatris, Zentiva, and Boehringer Ingelheim in the last three years outside of the submitted work. I. B., D. B., and M. Z. are employees of Amgen and hold Amgen stock. V. D., K. G., A. K., and L. T. declare that they have no known competing financial interests or personal relationships that may have influenced the work reported in this study.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
